Gossamer Bio, Inc. (GOSS)

NASDAQ: GOSS · IEX Real-Time Price · USD
9.02
+0.77 (9.33%)
At close: Dec 2, 2022 4:00 PM
9.47
+0.45 (4.99%)
After-hours: Dec 2, 2022 6:58 PM EST
9.33%
Market Cap 779.43M
Revenue (ttm) n/a
Net Income (ttm) -229.90M
Shares Out 91.18M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,475,860
Open 8.23
Previous Close 8.25
Day's Range 8.12 - 9.05
52-Week Range 5.64 - 15.2
Beta 0.88
Analysts Buy
Price Target 18.20 (+101.8%)
Earnings Date Nov 14, 2022

About GOSS

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disea... [Read more]

Industry Biotechnology
IPO Date Feb 8, 2019
CEO Sheila Gujrathi
Employees 185
Stock Exchange NASDAQ
Ticker Symbol GOSS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for GOSS stock is "Buy." The 12-month stock price forecast is 18.2, which is an increase of 101.77% from the latest price.

Price Target
$18.2
(101.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What Makes Gossamer Bio (GOSS) a New Buy Stock

Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago - Zacks Investment Research

Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 month ago - Business Wire

This little-known biopharma stock could rally 70%: Goldman Sachs

Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.

1 month ago - Invezz

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Vir...

2 months ago - Investors Business Daily

Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

3 months ago - Business Wire

Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy

Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.

4 months ago - Zacks Investment Research

Wall Street Analysts See a 52% Upside in Gossamer Bio (GOSS): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 52.4% in Gossamer Bio (GOSS). While the effectiveness of this highly sought-after metric is questionable, the pos...

4 months ago - Zacks Investment Research

Gossamer Bio Announces $120 Million Private Placement Financing

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

4 months ago - Business Wire

Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutin...

SAN DIEGO--(BUSINESS WIRE)---- $GOSS #ERSpublications--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing the...

5 months ago - Business Wire

Wall Street Analysts Believe Gossamer Bio (GOSS) Could Rally 113%: Here's is How to Trade

The mean of analysts' price targets for Gossamer Bio (GOSS) points to an 113.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana...

6 months ago - Zacks Investment Research

Gossamer Bio (GOSS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Gossamer Bio (GOSS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revi...

6 months ago - Zacks Investment Research

Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

6 months ago - Business Wire

Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program

Gossamer Bio Inc (NASDAQ: GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neith...

7 months ago - Benzinga

Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

7 months ago - Business Wire

Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

9 months ago - Business Wire

Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on ...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

9 months ago - Business Wire

Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the ...

1 year ago - Business Wire

Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Office...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and C...

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire

Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease ar...

1 year ago - Business Wire